Recently, a US-based drug developing company asked CNSintel to assess their development plans for a novel therapeutic strategy targeted for a neurodegenerative condition. We carefully selected 5 experts who had relevant multidisciplinary expertise in that area.
Once the client approved the selected group of experts suggested by us, and the experts confirmed their availability, the experts signed our confidentiality agreement. Subsequently, the client’s pre-clinical summary of data was shared with the experts and they carried out their detailed assessment of the therapeutic strategy, and provided additional scientific suggestions.
We then sent the reports from our experts back to the client within 28 days of commissioning the work from the experts. Our client was very pleased with the quality of the scientific assessment reports and informed us that they would be implementing some of the suggestions provided by our experts.